Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways

BACKGROUND: Paclitaxel (PTX) resistance is a major obstacle in the treatment of triple-negative breast cancer (TNBC). Previously, we have reported that interleukin-1 receptor-associated kinase 1 (IRAK1) and its downstream pathways are associated with PTX resistance in TNBC cells. In this study, we s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Panpan, Song, Dan, Wan, Danhong, Li, Lingyu, Mei, Wenhui, Li, Xiaoyun, Han, Li, Zhu, Xiaofeng, Yang, Li, Cai, Yu, Zhang, Ronghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2020
Materias:
Molecular Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275687/
https://www.ncbi.nlm.nih.gov/pubmed/32547883
http://dx.doi.org/10.7717/peerj.9281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275687/
https://www.ncbi.nlm.nih.gov/pubmed/32547883
http://dx.doi.org/10.7717/peerj.9281

Ejemplares similares